Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Breast Cancer Reports
Published in: Current Breast Cancer Reports 3/2016

01-09-2016 | Risk and Prevention (TB Bevers, Section Editor)

Update on Breast Cancer Risk Reduction Therapy

Author: Victor G. Vogel

Published in: Current Breast Cancer Reports | Issue 3/2016

Login to get access

Abstract

In women at increased risk of breast cancer age ≥35 years, the selective estrogen receptor modulator (SERM) tamoxifen should be discussed as an option to reduce the risk of estrogen receptor (ER)-positive breast cancer. In postmenopausal women, raloxifene, anastrozole, and exemestane should also be discussed as options for breast cancer risk reduction. Risk reduction with SERMs continues for at least 10 years in both premenopausal and postmenopausal women. Tamoxifen is not recommended for women with a history of deep vein thrombosis, pulmonary embolus, stroke, transient ischemic attack, or during prolonged immobilization. Chemoprevention with a SERM may be particularly beneficial to women with atypical hyperplasia, a 5-year risk of more than 5 %, in women with increased mammographic density, or in women with lobular carcinoma in situ. Aromatase inhibitor therapy is of value in high-risk postmenopausal women. Toxicity with tamoxifen is minimal in premenopausal women and is less with either raloxifene or an aromatase inhibitor in postmenopausal women.
Literature
1.
Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91:1829–46.CrossRefPubMed
2.•
Tice JA, Miglioretti DL, Li C-S, et al. Breast density and benign breast disease: risk assessment to identify women at high risk of breast cancer. J Clin Oncol. 2015;33:3137–43. Mammographic density in more than 50% of breast tissue is an independent risk factor for breast cancer and may identify women who are candidates for risk reduction with SERMs.
3.
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–88.CrossRefPubMed
4.
Powles TJ. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007;99:283–90.CrossRefPubMed
5.
Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian randomized tamoxifen prevention trial among women with hysterectomy. J Natl Cancer Inst. 2007;99:727–37.CrossRefPubMed
6.
Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer: 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99:272–82.CrossRefPubMed
7.
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 2005;97:1652–62.CrossRefPubMed
8.•
Cuzick J, Sestak, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;6:67–75. When follow-up was extended to 16 years, there was an enduring 30 % reduction in the risk of both ER-positive invasive breast cancer and DCIS even though active treatment with tamoxifen was stopped after 5 years. The magnitude of the benefit was as large in years 10 and later as it was in years 1–10.
9.
Cuzick J, Sestak I, Bonanni B, et al. SERM Chemoprevention of Breast Cancer Overview Group. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381:1827–34.CrossRefPubMedPubMedCentral
10.•
Hartmann LC, Degnim AC, Santen RJ, et al. Atypical hyperplasia of the breast—risk assessment and management options. N Engl J Med. 2015;372:78–89. Atypical lobular or ductal hyperplasia is a very high risk lesion with the risk of developing invasive breast cancer approaching 30 % at 25 years. The risk is nearly as large as that associated with predispopsing germline genetic mutations.
11.
Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA. 2006;295:2727–41.CrossRefPubMed
12.
Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res. 2010;3:696–706.CrossRef
13.
Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23:1111–30.CrossRefPubMed
14.
Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383:1041–48.CrossRefPubMed
15.
Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364:2381–91.CrossRefPubMed
16.
17.•
Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2013;31:2942–62. Evidence-based recommendations for the use of pharmacological agents to reduce the risk of invasive breast cancer in high-risk women with a thorough review of the randomized, clinical trials that support their use.
18.•
Nelson HD, Smith B, Griffin JC, Fu R. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;158:604–14. Rigorous evidence-based recommendations for the use of SERMs and aromatase inhibitors to reduce the risk of breast cancer in high-risk women.
19.
Cuzick J, DeCensi A, Arun B, et al. Preventive therapy for breast cancer: an international consensus statement. Lancet Oncol. 2011;12:496–503.CrossRefPubMed
20.
Freedman AN, Costantino JP, Gail MH, et al. A benefit/risk assessment tool for breast cancer chemoprevention treatment. J Clin Oncol. 2011;29:2327–33.CrossRefPubMedPubMedCentral
Metadata
Title
Update on Breast Cancer Risk Reduction Therapy
Author
Victor G. Vogel
Publication date
01-09-2016
Publisher
Springer US
Published in
Current Breast Cancer Reports / Issue 3/2016
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-016-0221-8

Other articles of this Issue 3/2016

Current Breast Cancer Reports 3/2016 Go to the issue

Invited Commentary

Aromatase Inhibitor-Associated Arthralgia: How Big Is the Problem and What Can Be Done?

Risk and Prevention (TB Bevers, Section Editor)

Physician and Patient Barriers to Breast Cancer Preventive Therapy

Clinical Trials (S Hurvitz, Section Editor)

Reducing the Risk of Breast Cancer Recurrence: an Evaluation of the Effects and Mechanisms of Diet and Exercise

Clinical Trials (S Hurvitz, Section Editor)

Screening for Cognitive Impairment Associated with Chemotherapy for Breast Cancer

Risk and Prevention (TB Bevers Section Editor)

Current Approach to Breast Cancer Risk Reduction for Women with Hereditary Predispositions to Breast Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits